Jupiter Topco LLC Makes New $358.65 Million Investment in Illumina, Inc. $ILMN

Jupiter Topco LLC bought a new position in Illumina, Inc. (NASDAQ:ILMN) in the second quarter, Holdings Channel.com reports. The fund bought 2,039,763 shares of the life sciences company’s stock, valued at approximately $358,652,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Fiduciary Financial Advisors acquired a new stake in shares of Illumina in the second quarter valued at $26,000. Keating Financial Advisory Services Inc. acquired a new position in Illumina during the second quarter worth about $32,000. Rakuten Securities Inc. acquired a new position in Illumina during the second quarter worth about $33,000. Elyxium Wealth LLC bought a new stake in Illumina in the fourth quarter worth about $25,000. Finally, TD Waterhouse Canada Inc. bought a new stake in Illumina in the fourth quarter worth about $26,000. 89.42% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts recently weighed in on ILMN shares. Wall Street Zen upgraded shares of Illumina from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. Stifel Nicolaus upped their price target on Illumina from $155.00 to $225.00 and gave the company a “buy” rating in a report on Friday, July 31st. Zacks Research upgraded Illumina from a “hold” rating to a “strong-buy” rating in a research report on Monday, August 3rd. TD Cowen raised their price objective on Illumina from $192.00 to $210.00 and gave the stock a “hold” rating in a research note on Friday, July 31st. Finally, Deutsche Bank Aktiengesellschaft cut Illumina to a “hold” rating in a report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Illumina presently has an average rating of “Hold” and an average target price of $188.40.

Insider Activity at Illumina

In other news, CAO Scott D. Ericksen sold 1,500 shares of Illumina stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $150.10, for a total value of $225,150.00. Following the transaction, the chief accounting officer directly owned 14,946 shares in the company, valued at approximately $2,243,394.60. The trade was a 9.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Christensen Jakob Wedel sold 1,033 shares of Illumina stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total value of $197,840.16. Following the completion of the transaction, the senior vice president directly owned 14,023 shares in the company, valued at approximately $2,685,684.96. This represents a 6.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 2,095,958 shares of company stock valued at $401,720,974. Corporate insiders own 2.90% of the company’s stock.

Illumina Stock Performance

ILMN stock opened at $224.99 on Wednesday. The firm has a 50 day simple moving average of $190.35 and a 200 day simple moving average of $153.78. Illumina, Inc. has a 52 week low of $88.00 and a 52 week high of $226.84. The stock has a market cap of $33.97 billion, a P/E ratio of 41.98, a P/E/G ratio of 3.14 and a beta of 1.45. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The firm had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. During the same quarter in the previous year, the company posted $1.19 earnings per share. The business’s quarterly revenue was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Research analysts anticipate that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.